TABLE 5

Changes between baseline and 3 months in troglitazone responders according to magnitude of decrease in IVGTT insulin area during first 3 months

Small decrease*Large decreaseP
n4231
Fasting glucose (mg/dl)−3.0 (−15.0, 10.0)−7.0 (−26.0, 1.0)0.007
Kg (min−1/100)−0.02 (−0.66, 1.75)0.17 (−1.69, 1.19)0.30
SI (min−1 per μU/ml × 10−4)1.49 (0.54, 7.69)1.34 (0.54, 4.40)0.63
Total insulin area (μU/ml × min)−1591 (−3053, 985)−6011 (−19364, −3160)<0.000
AIRg (μU/ml × min)−3 (−424, 364)−126 (−926, 255)0.06
DI428 (−727, 2416)689 (−1822, 2732)0.08
Pill compliance (% of prescribed)§93 (46, 99)90 (62, 98)0.54
  • Data are median (minimum, maximum).

  • *

    * Responders with change in IVGTT insulin area in tertiles 1 and 2, Table 3;

  • Responders with change in IVGTT insulin area in tertile 3, Table 3;

  • P < 0.01 for change from baseline within a group by Wilcoxon’s signed-rank test;

  • §

    § during first 3 months on trial.